Pharmaceuticals

Lyme Disease Vaccine Market Growth Expected To Reach $2.22 Billion By 2030 At 11.7% CAGR

May 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Lyme Disease Vaccine Market Expected To Scale Between 2026 And 2030?

The lyme disease vaccine market has shown robust expansion in recent years. It is anticipated to grow from $1.12 billion in 2025 to $1.2 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. The historical development of this market is attributable to a rising incidence of lyme disease in endemic areas, the past limitations of solely antibiotic-based treatment methods, initial vaccine research efforts, increased public understanding of tick-borne infections, and improvements in public health surveillance.

The lyme disease vaccine market is anticipated to undergo significant expansion over the coming years. This market is projected to reach $1.57 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.0%. This predicted growth can be ascribed to several factors, including the spread of vaccination initiatives in regions where the disease is prevalent, greater financial commitment towards preventing infectious diseases, progress in developing advanced vaccine technologies, an uptick in the use of combination vaccines, and an intensified worldwide effort to manage zoonotic diseases. Key developments expected during this period involve improvements in recombinant vaccine technologies, a heightened emphasis on proactive immunization strategies, an increase in clinical studies for illnesses transmitted by ticks, a growing demand for enduring immunity options, and strengthening partnerships between public and private health entities.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30317&type=smp

Which Major Drivers Are Influencing The Expansion Of The Lyme Disease Vaccine Market?

The rising incidence of Lyme disease is projected to fuel the expansion of the Lyme disease vaccine market moving forward. Lyme disease, a tick-borne ailment caused by Borrelia bacteria, manifests with fever, fatigue, and a rash, and can potentially lead to severe joint, heart, or neurological issues if left untreated. This increased prevalence of Lyme disease is attributed to climate change, where warmer temperatures and milder winters extend tick habitats, thereby heightening human exposure to infected ticks. Lyme disease vaccines contribute to prevention by educating the immune system to recognize and combat Borrelia bacteria, thereby lowering the chances of infection. They simplify the management of the disease by offering long-term protection, which enhances public health outcomes. For instance, in March 2025, according to the Centers for Disease Control and Prevention, a US-based federal health agency, approximately 89,000 cases of Lyme disease were reported in the United States in 2023, while alternative estimation methods suggest that around 476,000 individuals might be diagnosed and treated for Lyme disease annually. Therefore, the growing prevalence of Lyme disease is a primary driver for the Lyme disease vaccine market’s growth.

What Segment Categories Shape The Lyme Disease Vaccine Market Segment Landscape?

The lyme disease vaccine market covered in this report is segmented –

1) By Vaccine Type: Recombinant Vaccines, Subunit Vaccines, Live Attenuated Vaccines, Other Vaccine Types

2) By Technology: Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Nucleic Acid Test, Serological Test

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals And Clinics, Pharmacies, Government Supply, Other Distribution Channels

5) By End User: Hospitals, Clinical Laboratories, Other End Users

Subsegments:

1) By Recombinant Vaccines: Protein-Based Recombinant Vaccines, Vector-Based Recombinant Vaccines, Deoxyribonucleic Acid (DNA)-Based Recombinant Vaccines

2) By Subunit Vaccines: Protein Subunit Vaccines, Polysaccharide Subunit Vaccines, Conjugate Subunit Vaccines

3) By Live Attenuated Vaccines: Naturally Attenuated Vaccines, Genetically Attenuated Vaccines, Temperature-Sensitive Attenuated Vaccines

4) By Other Vaccine Types: Toxoid Vaccines, Inactivated Vaccines, Vectored Vaccines

Which Trends Are Shaping The Lyme Disease Vaccine Market?

Leading companies within the Lyme disease vaccine market are concentrating on developing their advanced product candidates, particularly booster vaccines, with the aim of addressing medical gaps, bolstering immune defense, and streamlining vaccination schedules. Booster vaccines are supplemental doses administered following initial immunization to re-establish or strengthen sustained immunity. For example, in September 2025, Valneva SE, a France-based biotechnology firm, verified encouraging immunogenicity and safety results from its continuing Phase 2 study for the Lyme disease vaccine candidate, VLA15. This is a multivalent vaccine designed to instruct the immune system to generate antibodies targeting OspA proteins found on Borrelia bacteria. When a tick bite occurs, these antibodies intercept the bacteria within the tick, thereby preventing human infection. The robust immune reaction and positive safety profile observed after a third booster dose mirrored findings from earlier annual booster doses, further confirming its alignment with the expected advantages of a yearly vaccination before each Lyme season. This booster approach seeks to offer ongoing protection against Lyme disease, highlighting the possibility of an annual pre-exposure season booster to simplify safeguarding for individuals at risk.

Who Are The Companies Operating Across The Lyme Disease Vaccine Market Value Chain?

Major companies operating in the lyme disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Boehringer Ingelheim GmbH, University of Pennsylvania, Elanco Animal Health Incorporated, Zoetis Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Aegis Life Inc., Bioveta a.s., Dynavax Technologies Corporation, Valneva SE, MassBiologics of UMass Chan Medical School, Inovio Pharmaceuticals Inc., US Biologic Inc., Blue Lake Biotechnology Inc.

Get The Full Lyme Disease Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/global-lyme-disease-vaccine-market-report

Which Region Represents The Largest Share Of The Lyme Disease Vaccine Market?

North America was the largest region in the Lyme disease vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Lyme Disease Vaccine Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/global-lyme-disease-vaccine-market-report

Browse Through More Reports Similar to the Global Lyme Disease Vaccine Market 2026, By The Business Research Company

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Dog Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795